Absci Reports Q1 Revenue Miss and Widened Loss, Advances Pipeline with Extended Cash Runway
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci Corp reported a significant Q1 2026 revenue decline and widened net loss, but highlighted positive clinical pipeline progress and an extended cash runway into the first half of 2028.
Key Events · Earnings and Guidance · ABSI
-
Q1 2026 Financial Results
The company reported a substantial 83% decrease in partner program revenue to $0.2 million and a widened net loss of $29.6 million for the first quarter ended March 31, 2026.
-
Extended Cash Runway
Absci projects its cash, cash equivalents, and marketable securities of $125.7 million as of March 31, 2026, will be sufficient to fund operating plans into the first half of 2028.
-
ABS-201 Clinical Progress
The Phase 1/2a HEADLINE trial for ABS-201 in androgenetic alopecia successfully dosed all SAD cohorts with favorable safety, initiated MAD cohorts, and anticipates key data readouts in Q2 and 2H 2026. Phase 2 for endometriosis is expected to initiate in Q4 2026.
-
Pipeline Expansion
Absci added ABS-202, a second novel anti-PRLR antibody, to its internal pipeline, currently in preclinical development for an undisclosed inflammation and immunology indication.
Analysis · ABSI · Industrial Applications And Services
Absci Corp's Q1 2026 results show a substantial 83% decrease in partner program revenue and a widened net loss, indicating significant financial challenges. However, the company also reported positive clinical progress for its lead asset, ABS-201, in both androgenetic alopecia and endometriosis, alongside the addition of a new preclinical program, ABS-202. Critically, the company projects its cash and marketable securities will fund operations into the first half of 2028, providing a crucial extended runway despite the losses. This filing presents a mixed picture of poor financial performance balanced by operational advancements and improved liquidity outlook, making it important for investors to assess the company's trajectory.
At the time of this filing, ABSI was trading at $5.52 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $893.8M. The 52-week trading range was $2.24 to $6.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.